glutaminyl cyclase

Glutaminyl Cyclase Inhibitor 5 is a potent, selective inhibitor of human glutaminyl cyclase (hQC), demonstrating an inhibition concentration half-max (IC 50) of 3.2 nM.

Glutaminyl Cyclase Inhibitor 1, a glutaminyl cyclase inhibitor with an IC50 of 0.5 μM, can be utilized for studying neurological disorders.

Glutaminyl Cyclase Inhibitor 3, a designed anti-Alzheimer's compound, is a potent human Glutaminyl Cyclase (GC) inhibitor (IC50: 4.5 nM). It significantly reduced the brain concentrations of pyroform Aβ and total Aβ and restored cognitive functions.

Glutaminyl Cyclase Inhibitor 4 is a potent, selective glutaminyl cyclase (QC) inhibitor (IC50: 6.1 nM). It is a potent anti-Alzheimer's agent.

Glutaminyl Cyclase Inhibitor 2 is a glutaminyl cyclase inhibitor with an IC50 of 1.23 μM.

Glutaminyl cyclases-IN-2 (compound 27) serves as a potent inhibitor of glutaminyl cyclase, displaying an IC50 value of 0.08 μM. This compound plays a crucial role in cancer research.

Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent inhibitor of Glutaminyl cyclases (QC), acting on human QC with an IC50 of 12 nM and on isoQC with an IC50 of 73 nM. It selectively inhibits isoQC, blocks CD47 SIRPα interaction, and enhances phagocytosis in THP-1 and U937 macrophages.

SEN177 shows the potential in the research of Huntington's disease that is a potent inhibitor of glutaminyl cyclase (QPCT) with an IC 50 of 0.013μM for glutaminyl-peptide cyclotransferase-like (QPCTL). The Ki value of SEN177 for human glutaminyl cyclase (hQC) is 20 nM. SEN177 significantly reduces the early stages of mutant HTT oligomerisation and reduces the percentage of neurons with Q80 aggregates [1].

PBD-150 is an inhibitor of human glutaminyl cyclase (hQC) Y115E-Y117E variant( ki : 490 nM)